Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

(2014) Aristoteles Giagounidis et al.   CANCER

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

(2013) C. Kelaidi et al.   ANNALS OF HEMATOLOGY

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

(2013) L. Malcovati et al.   BLOOD

Clinical and biological implications of driver mutations in myelodysplastic syndromes

(2013) E. Papaemmanuil et al.   BLOOD

Transplantation for myelodysplastic syndromes 2013

(2013) Jennifer E. Vaughn et al.   CURRENT OPINION IN HEMATOLOGY

A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

(2013) S. D. Gore et al.   HAEMATOLOGICA

Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome

(2013) David Valcárcel et al.   JOURNAL OF CLINICAL ONCOLOGY

Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database

(2013) Maria Teresa Voso et al.   JOURNAL OF CLINICAL ONCOLOGY

Monosomal karyotype in MDS: explaining the poor prognosis?

(2013) J Schanz et al.   LEUKEMIA

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

(2013) C Kelaidi et al.   LEUKEMIA

Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data

(2013) Ronald Brand et al.   PLoS One

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

(2012) B. Will et al.   BLOOD

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

(2012) P. L. Greenberg et al.   BLOOD

Lenalidomide for Treatment of Myelodysplastic Syndromes

(2012) Rami S. Komrokji et al.   CURRENT PHARMACEUTICAL DESIGN

Genome-wide aberrant DNA methylation of microRNA host genes in hepatocellular carcinoma

(2012) Jing Shen et al.   Epigenetics

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

(2012) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

(2012) T M Westers et al.   LEUKEMIA

Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry

(2012) Judith Neukirchen et al.   LEUKEMIA RESEARCH

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

(2011) P. Fenaux et al.   BLOOD

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

(2011) David Sibon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes

(2011) Noémi B. A. Roy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Therapy-related myeloid neoplasms

(2011) Giuseppe Leone et al.   CURRENT OPINION IN ONCOLOGY

Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome

(2011) Jaroslav Cermak et al.   HEMOGLOBIN

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

(2011) Julie Schanz et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

(2011) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

(2011) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study

(2011) Shiqiang Qu et al.   LEUKEMIA & LYMPHOMA

Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry

(2011) Judith Neukirchen et al.   LEUKEMIA RESEARCH

Frequent pathway mutations of splicing machinery in myelodysplasia

(2011) Kenichi Yoshida et al.   NATURE

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

(2011) Rafael Bejar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Myelodysplastic Syndromes in People Exposed to Ionizing Radiation: A Retrospective Cohort Study of Nagasaki Atomic Bomb Survivors

(2010) Masako Iwanaga et al.   JOURNAL OF CLINICAL ONCOLOGY

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

(2010) Christian Rose et al.   LEUKEMIA RESEARCH

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

(2010) Norbert Gattermann et al.   LEUKEMIA RESEARCH

The lower risk MDS patient at risk of rapid progression

(2010) Moshe Mittelman et al.   LEUKEMIA RESEARCH

Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?

(2009) V. Pullarkat   BLOOD

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

(2009) P. L. Greenberg et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Impact of iron overload in myelodysplastic syndromes

(2009) Pierre Fenaux et al.   BLOOD REVIEWS

Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major

(2009) P. Kirk et al.   CIRCULATION

Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions

(2009) P. Valent et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

(2009) R. Gurion et al.   HAEMATOLOGICA

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Mutation inTET2in Myeloid Cancers

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Myelodysplastic Syndromes

(2009) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Red Blood Cell Transfusion Dependence and Outcome after Allogeneic Peripheral Blood Stem Cell Transplantation in Patients with de Novo Myelodysplastic Syndrome (MDS)

(2008) Uwe Platzbecker et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

(2008) Janice Gabrilove et al.   BRITISH JOURNAL OF HAEMATOLOGY

Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy

(2008) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome

(2008) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes

(2008) Matteo Giovanni Della Porta et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

(2008) C. Kelaidi et al.   LEUKEMIA RESEARCH

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

(2007) S. Park et al.   BLOOD